Health Chat for lifestyle planning in people with multiple cardiometabolic conditions
Health Chat for Empowerment-based Lifestyle Planning for Cardiometabolic Multimorbidity (HcELP_CMM) Program: a Randomized Controlled Trial Study
NA · The University of Hong Kong · NCT07158697
This program tests whether a 12-week face-to-face and WeChat-based Health Chat can help adults with two or more cardiometabolic conditions improve lifestyle habits and health.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 232 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong (other) |
| Locations | 3 sites (Suzhou, Jiangsu and 2 other locations) |
| Trial ID | NCT07158697 on ClinicalTrials.gov |
What this trial studies
This two-part project uses a single-blind, parallel-group, randomized design comparing a 12-week Health Chat empowerment program to usual care in adults with cardiometabolic multimorbidity. The intervention combines an individualized, one-hour face-to-face goal-oriented counseling session with a subsequent WeChat-based personalized lifestyle empowerment program that includes goal setting and measurable biofeedback. Part 1 is a mixed-method pilot (randomized trial followed by qualitative interviews) and Part 2 is a full randomized controlled trial, with participants randomized 1:1 to intervention or usual care. Primary outcomes include feasibility and acceptability, with short- and long-term measures of lifestyle behaviors, cardiometabolic indicators, symptom burden, health-related quality of life, psychological well-being, and physical function.
Who should consider this trial
Good fit: Adults aged 18 or older with two or more cardiometabolic conditions (for example hypertension, type 2 diabetes, stroke, heart disease, dyslipidemia, or obesity) who can use WeChat and attend community health centers in Suzhou.
Not a fit: People with contraindications to exercise (severe musculoskeletal or cardiovascular disease), serious psychiatric illness, significant cognitive impairment, sensory or communication barriers, or without a WeChat-capable device are unlikely to be eligible or benefit.
Why it matters
Potential benefit: If successful, the program could help people with multiple cardiometabolic conditions adopt and sustain healthier behaviors, improve cardiometabolic risk markers, reduce symptoms, and enhance quality of life.
How similar studies have performed: Related digital coaching and empowerment programs have shown modest short-term improvements in lifestyle behaviors and cardiometabolic risk in other populations, but tailored empowerment interventions for cardiometabolic multimorbidity remain relatively novel with mixed evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults aged 18 years or above； 2. Diagnosed with cardiometabolic multimorbidity (CMM), which was defined as co-existing with two or more cardiometabolic diseases, including primary hypertension, type 2 diabetes, stroke, heart diseases (eg. coronary heart disease, arrhythmia, heart failure, myocardial infarction, and cardiac valve diseases), dyslipidemia, and obesity; 3. Possessed a digital device installed with WeChat, as well as with an internet connection. Exclusion Criteria: 1. Contraindications to exercise according to American College of Sports Medicine (ACSM), such as severe musculoskeletal disorders, severe cardiovascular diseases, or spinal nerve injury; 2. Diagnosis of psychiatric disease; 3. Has impaired cognitive function as indicated by an Abbreviated Mental Test Score (AMTS) ≤6; 4. Has impaired sensory or communication function which hider them participation in this program, such as hearing loss, vision loss, and unable to speak Mandarin.
Where this trial is running
Suzhou, Jiangsu and 2 other locations
- Gusu District Feng Men Street Community Health Service Center — Suzhou, Jiangsu, China (RECRUITING)
- Gusu District Jinchang Street Bailian Community Health Service Center — Suzhou, Jiangsu, China (RECRUITING)
- Gusu District Shuang Ta Street Jinfan Community Health Service Center — Suzhou, Jiangsu, China (RECRUITING)
Study contacts
- Principal investigator: Jing Xi, PhD — The University of Hong Kong
- Study coordinator: Jing Xi, PhD
- Email: u3010484@connect.hku.hk
- Phone: 0086-15850061924
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiometabolic Diseases, Multimorbidity, Cardiometabolic multimorbidity, Empowerment, Patient-centered, Self-management, Intervention